Why the First Clinical Cure for HIV Will Likely be Developed in Maryland By Chris Frew | September 18, 2023 As was true in the 1980s, Maryland’s DNA Valley remains [….]
Why the First Clinical Cure for HIV Will Likely be Developed in Maryland

Why the First Clinical Cure for HIV Will Likely be Developed in Maryland By Chris Frew | September 18, 2023 As was true in the 1980s, Maryland’s DNA Valley remains [….]
CEO Jeff Galvin and American Gene Technologies’ Spinoff, AddImmune, Offer Hope to End the HIV Epidemic August 9, 2023 This transcript originally appeared via Think – a national technology and operations [….]
American Gene Technologies Celebrates Phase I Success of Experimental HIV Cell Therapy By Alex KeownJune 13, 2023 American Gene Technologies (AGT) is one step closer to making history with a [….]
American Gene Technologies Spins Off Addimmune as a Separate Company With a Focus on Curing HIV By Alex KeownJune 9, 2023 Powered by promising Phase I results from its HIV [….]
5 Questions With Layla Ghaffari, Associate Scientist at American Gene Technologies June 6, 2023 “5 Questions With…” is a recurring BioBuzz series where we reach out to interesting people to [….]
Karen McCord Hired as Chief of Staff for American Gene Technologies
Kenneth G. Hadley Joins American Gene Technologies® as People and Culture Manager
Temple Researchers and Biotech Spinoff Chase an HIV Cure By Mark TerryMay 4, 2023 Three people have been known to have been “cured” of HIV, meaning that the virus was [….]
Upcoming 3rd Annual BioBuzz Awards to Celebrate Winners from Maryland, Philadelphia In addition to the reception, the event will also feature several panels comprised of esteemed local key opinion leaders [….]
You likely know AGT best from their ongoing work to develop a potential HIV cure. Their lead candidate, AGT103-T, is currently in a Phase 1 trial and has shown encouraging data thus far both in patient safety and T cell responses. The company is currently planning for Phase 2.